NYSE:PTHN - Patheon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$34.98
Today's Range$34.98 - $34.98
52-Week Range$23.72 - $35.13
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive PTHN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Previous SymbolNASDAQ:PTHN



Sales & Book Value

Annual Sales$1.87 billion



Next Earnings DateN/A
OptionableNot Optionable

Patheon (NYSE:PTHN) Frequently Asked Questions

What is Patheon's stock symbol?

Patheon trades on the New York Stock Exchange (NYSE) under the ticker symbol "PTHN."

How were Patheon's earnings last quarter?

Patheon NV (NYSE:PTHN) announced its earnings results on Thursday, June, 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. The company earned $483.40 million during the quarter, compared to analysts' expectations of $466.08 million. The company's revenue was up 3.2% compared to the same quarter last year. View Patheon's Earnings History.

Has Patheon been receiving favorable news coverage?

News coverage about PTHN stock has been trending negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Patheon earned a news impact score of -2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Patheon's key competitors?

What other stocks do shareholders of Patheon own?

Who are Patheon's key executives?

Patheon's management team includes the folowing people:
  • Paul S. Levy, Chairman of the Board
  • James C. Mullen, Chief Executive Officer, Director
  • Stuart R. Grant, Chief Financial Officer, Executive Vice President
  • Gilles A. Cottier, President - Global Pharmaceutical Development Services
  • Franco Negron, President - Drug Product Services
  • Lukas Utiger, President - Drug Substance
  • Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
  • Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
  • Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
  • Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement

When did Patheon IPO?

(PTHN) raised $625 million in an initial public offering (IPO) on Thursday, July 21st 2016. The company issued 30,500,000 shares at a price of $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities served as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

How do I buy shares of Patheon?

Shares of PTHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Patheon?

Patheon has a market capitalization of $0.00 and generates $1.87 billion in revenue each year.

What is Patheon's official website?

The official website for Patheon is http://www.patheon.com.

How can I contact Patheon?

Patheon's mailing address is Herengracht 483, Amsterdam P7, 1017BT. The company can be reached via phone at 31-20-622-3243.

MarketBeat Community Rating for Patheon (NYSE PTHN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  349
MarketBeat's community ratings are surveys of what our community members think about Patheon and other stocks. Vote "Outperform" if you believe PTHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: 12b-1 Fees

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel